Fundamentals Hub
▼ FY 2025 Summary Analysis
Annual report ending Dec 31, 2025Overview and Growth
ABEONA THERAPEUTICS INC. generated $5.82M of revenue in fiscal 2025, with net income of $71.18M and an operating cash outflow of $76.33M. Revenue of $5.82M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Diluted earnings per share were $1.01, translating the period’s attributable earnings into the amount reported for each diluted share. At period end, total assets were $219.57M, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.03x, relating the company’s annual revenue directly to the total assets reported at the period end.Profitability
After reported cost of revenue, the company retained $4.29M as gross profit before recognizing operating expenses and other items. Gross profit represented 73.7% of revenue, showing how much of the top line remained after direct costs. The company recorded an operating loss of $89.45M after the reported operating expense base. Net income came to $71.18M, completing the progression from revenue through gross and operating profitability to the final reported result. Negative EBITDA totaled $86.95M, confirming that the earnings deficit remained before depreciation and amortization. Pretax income was $71.28M, isolating the reported earnings outcome before the income-tax provision recognized for the fiscal year. The reported income-tax provision was $100.00K, the amount recognized between pretax income and the final net-income result. The income-tax provision equaled 0.1% of pretax income, showing the tax burden absorbed by the year’s earnings. The relationship between net income and period-end equity was 44.7%, indicating the profitability achieved on book capital. Return on period-end assets was 32.4%, connecting net income with the company’s total asset base. The bottom line improved from a $63.73M loss in fiscal 2024 to $71.18M of income.Liquidity and Capital Structure
The company held $219.57M of assets against $60.35M of liabilities and $159.22M of equity, revealing how the asset base was financed. At period end, current assets of $204.91M compared with current liabilities of $29.57M, defining the company’s short-term resource position. Current assets covered current liabilities by 6.93x, leaving a positive buffer for near-term obligations. The company held $78.44M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 265.3% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Total debt was $20.04M, establishing the amount of borrowing carried within the company’s capital structure. Debt equaled 0.13x of book equity, describing the relative scale of borrowing and shareholder capital. The debt-to-assets relationship was 9.1%, comparing borrowing with the total asset balance. Book equity represented 72.5% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 27.5% of total assets, quantifying the liability-funded share of the company’s resource base. Measured against total assets, cash and equivalents represented 35.7%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $108.93M in fiscal 2024, the current asset base moved 101.6% and finished higher. Against $44.03M of equity in fiscal 2024, the current book-equity balance moved 261.6% and ended higher. Cash and equivalents were 235.8% higher than fiscal 2024 cash of $23.36M, showing the year-over-year change in liquid resources.Cash Flow and Earnings Quality
Cash flow from operations was an outflow of $76.33M, showing that operations absorbed cash during the period. The company spent $7.97M on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. The company recorded a $84.30M cash deficit after capital spending for the period. The free-cash-flow deficit equaled 38.4% of total assets, placing the cash shortfall against the company’s resource base.
Based on the annual report for the fiscal year ending Dec 31, 2025.
Analysis generated .